SG11202006047RA - Small molecule modulators of pantothenate kinases - Google Patents

Small molecule modulators of pantothenate kinases

Info

Publication number
SG11202006047RA
SG11202006047RA SG11202006047RA SG11202006047RA SG11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA
Authority
SG
Singapore
Prior art keywords
small molecule
molecule modulators
pantothenate kinases
pantothenate
kinases
Prior art date
Application number
SG11202006047RA
Other languages
English (en)
Inventor
Richard Lee
Rajendra Tangallapally
Charles Rock
Suzanne Jackowski
Anne Edwards
Mi Yun
Chitra Subramanian
Robert Zamboni
T Reddy
Original Assignee
St Jude Childrens Res Hospital Inc
Coa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital Inc, Coa Therapeutics Inc filed Critical St Jude Childrens Res Hospital Inc
Publication of SG11202006047RA publication Critical patent/SG11202006047RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202006047RA 2017-12-27 2018-12-26 Small molecule modulators of pantothenate kinases SG11202006047RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762610835P 2017-12-27 2017-12-27
PCT/US2018/067539 WO2019133635A1 (en) 2017-12-27 2018-12-26 Small molecule modulators of pantothenate kinases

Publications (1)

Publication Number Publication Date
SG11202006047RA true SG11202006047RA (en) 2020-07-29

Family

ID=67068124

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006047RA SG11202006047RA (en) 2017-12-27 2018-12-26 Small molecule modulators of pantothenate kinases

Country Status (12)

Country Link
US (1) US11891378B2 (pt)
EP (1) EP3731844A4 (pt)
JP (1) JP7352565B2 (pt)
KR (1) KR20200130242A (pt)
CN (1) CN111818922B (pt)
AU (1) AU2018395222B2 (pt)
BR (1) BR112020012875A2 (pt)
CA (1) CA3086671A1 (pt)
IL (1) IL275658B2 (pt)
MX (1) MX2020006754A (pt)
SG (1) SG11202006047RA (pt)
WO (1) WO2019133635A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006047RA (en) 2017-12-27 2020-07-29 St Jude Childrens Res Hospital Inc Small molecule modulators of pantothenate kinases
EP3731859A4 (en) 2017-12-27 2021-09-22 St. Jude Children's Research Hospital, Inc. METHODS OF TREATMENT FOR DISORDERS ASSOCIATED WITH CASTOR
WO2020198526A2 (en) * 2019-03-27 2020-10-01 St. Jude Children's Research Hospital Small molecule modulators of pank
WO2020203609A1 (ja) * 2019-03-29 2020-10-08 日本ケミファ株式会社 掻痒を治療するためのt型カルシウムチャネル阻害剤の使用
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用
WO2023230560A1 (en) * 2022-05-26 2023-11-30 Coa Therapeutics, Inc. Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894063B2 (en) 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
ES2329356T3 (es) 2002-06-12 2009-11-25 Chemocentryx, Inc. Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias.
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
RU2006105716A (ru) 2003-07-30 2007-09-10 Зинон Фармасьютиклз Инк. (Ca) Производные пиридазина и их применение в качестве терапевтических средств
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
JP2007538106A (ja) 2004-05-20 2007-12-27 イーラン ファーマスーティカルズ、インコーポレイテッド γセクレターゼのN−環式スルホンアミド阻害剤
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
EP2089018A2 (en) 2006-11-07 2009-08-19 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
WO2010115067A2 (en) 2009-04-02 2010-10-07 University Of Florida Research Foundation, Inc. Engineering the pathway for succinate production
CN101294194A (zh) * 2007-04-28 2008-10-29 江苏先声药物研究有限公司 泛酸激酶药物筛选模型及其应用
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
MX2012002532A (es) 2009-09-01 2012-04-11 Novozymes Inc Metodos para mejorar la produccion de acido malico en hongos filamentosos.
US9187772B2 (en) 2010-09-01 2015-11-17 University Of Florida Research Foundation, Inc. L-malate production by metabolically engineered escherichia coli
AU2011307304C1 (en) 2010-09-27 2016-10-20 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
WO2013004642A1 (en) 2011-07-01 2013-01-10 Remynd Nv 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
EP3060570B1 (en) * 2013-10-25 2018-09-19 Retrophin, Inc. Pantothenate derivatives for the treatment of neurological disorders
AU2016249021A1 (en) 2015-04-17 2017-10-19 Assembly Biosciences, Inc. Hepatitis B viral assembly effectors
EP3474667A4 (en) 2016-06-23 2019-11-27 St. Jude Children's Research Hospital, Inc. SMALL MOLECULAR MODULATORS OF PANTOTHENAT KINASES
EP3731859A4 (en) 2017-12-27 2021-09-22 St. Jude Children's Research Hospital, Inc. METHODS OF TREATMENT FOR DISORDERS ASSOCIATED WITH CASTOR
SG11202006047RA (en) 2017-12-27 2020-07-29 St Jude Childrens Res Hospital Inc Small molecule modulators of pantothenate kinases
WO2019133634A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
WO2022133034A1 (en) 2020-12-16 2022-06-23 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor

Also Published As

Publication number Publication date
CN111818922B (zh) 2023-06-13
CN111818922A (zh) 2020-10-23
EP3731844A1 (en) 2020-11-04
RU2020124599A (ru) 2022-01-27
AU2018395222B2 (en) 2023-06-08
WO2019133635A1 (en) 2019-07-04
JP2021508739A (ja) 2021-03-11
CA3086671A1 (en) 2019-07-04
EP3731844A4 (en) 2021-08-18
BR112020012875A2 (pt) 2021-01-05
IL275658B2 (en) 2024-04-01
US20210061788A1 (en) 2021-03-04
KR20200130242A (ko) 2020-11-18
US11891378B2 (en) 2024-02-06
JP7352565B2 (ja) 2023-09-28
AU2018395222A1 (en) 2020-08-13
IL275658B1 (en) 2023-12-01
MX2020006754A (es) 2021-01-29
IL275658A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
IL283582A (en) ror - gamma modulators
HK1256599A1 (zh) ROR-γ的調節劑
IL268820B (en) Diaryl macrocycles as protein kinase modulators
IL263649B (en) Small molecule modulators of pantothenate kinases
IL259342B (en) Modulators of chemokine receptors
HK1250999A1 (zh) Ror1-ror2結合的調節劑
IL275658A (en) Small molecule modulators of pantothenate kinases
GB201700711D0 (en) Application of an optical effect
IL266261A (en) ror-gamma modulators
GB201716468D0 (en) Modulators
IL271359A (en) Modulators of alpha-synuclein
IL274231A (en) Modulators of ENAC expression
GB2563095B (en) Modulators
IL271332B (en) Tetrahydropyridopyrazine modulators of gpr6
GB201702926D0 (en) Modulators
GB201706043D0 (en) Small molecules
GB201706042D0 (en) Small molecules
EP3417064A4 (en) KLK3 ACTIVATOR RNA MODULATORS